Reuters
Jan 2 () - Teva Pharmaceutical Industries Ltd said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc over its generic Cinacalcet HCl product.
The Israel-based drugmaker has also agreed to stop selling the generic product until its license date in mid-year 2021, or earlier under certain (graphic).
Teva said it recently received approval for the generic product and launched it in the United States.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Explore World Markets
ExploreMost Popular
- The 5 Largest Economies In The World And Their Growth In 2020
- From Harvard to Nasdaq Listing: Grab CEO's Ride to World's Biggest SPAC Deal
- CRU-CESCO-Chile´s Antofagasta says surging copper price not enough to entice big investments
- Egypt, Ukraine under review for inclusion in JPMorgan's GBI-EM indexes